A practical reference on Nuclear receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-17. Anything still debated is marked as such rather than presented as settled.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Compactituberculate - The dome-shaped tops of the shell units form a dense covering of nodes on the surface of the eggshell. This type of ornamentation is most commonly seen in megaloolithids. Sagenotuberculate - The nodes and ridges form a netlike pattern interspersed with pits and grooves. Dispersituberculate - Scattered nodes. This ornamentation is seen on the poles of elongated eggs, which may have allowed accumulations CO2 at the poles to escape between the nodes. Lineartuberculate - Ridges, and chains of ridges and nodes form lines parallel to the long axis of the egg. Ramotuberculate - Irregular chains of nodes, typically found as a transition between the lineartuberculate midsection and dispersituberculate ends of elongated eggs. Anastomotuberculate - Ridges similar to lineartuberculate, but instead form wavy, branching, or anastomosing patterns resembling the water ripple marks in sand.
A week later, on 13 March, Stalin responded vigorously to the speech, saying Churchill could be compared to Adolf Hitler insofar as he advocated the racial superiority of English-speaking nations so that they could satisfy their hunger for world domination, and that such a declaration was "a call for war on the USSR." The Soviet leader also dismissed the accusation that the USSR was exerting increasing control over the countries lying in its sphere. He argued that there was nothing surprising in "the fact that the Soviet Union, anxious for its future safety, [was] trying to see to it that governments loyal in their attitude to the Soviet Union should exist in these countries."
=== Legal action === In May 2019, in the first successful prosecution of top pharmaceutical executives for crimes related to the prescribing of opioids, the founder and four former executives of Insys Therapeutics Inc. were convicted by a federal jury in Boston in connection with bribing medical practitioners to prescribe Subsys, a highly-addictive sublingual fentanyl spray intended for cancer patients experiencing breakthrough pain, and for defrauding Medicare and private insurance carriers. The company declared bankruptcy about two weeks after they lost the case. Dozens of states are suing pharmaceutical companies, accusing them of causing the epidemic. Suits filed by almost 2,000 cities, counties, and tribal lands have been rolled into a single federal case scheduled to be heard in Fall 2019. In the first state case to reach a decision, on August 26, 2019, Oklahoma district court judge Thad Balkman found the pharmaceutical company Johnson & Johnson responsible for creating a "public nuisance" under state law, and ordered the company to pay a fine of $572 million. The company said they will appeal. Two other drug makers had previously settled with the state of Oklahoma. Purdue Pharma, the maker of OxyContin, agreed to a fine of $270 million in March 2019, and Teva Pharmaceuticals, which makes generic drugs, agreed to pay $85 million in May.
=== Differential diagnosis === While Gilbert syndrome is considered harmless, it is clinically important because it may give rise to a concern about a blood or liver condition, which could be more dangerous. However, these conditions have additional indicators:
== Medical uses == Oliceridine is indicated for short-term intravenous use in hospitals or other controlled clinical settings, such as during inpatient and outpatient procedures. It is not indicated for at-home use.
Sources: en.wikipedia.org
At the San Sebastián International Film Festival, he was awarded the Donostia Lifetime Achievement Award and became the youngest recipient of the award. The same year, he also starred in the disaster drama film The Impossible opposite Naomi Watts and Tom Holland. In 2013, McGregor starred alongside Meryl Streep and Julia Roberts in August: Osage County, which was based on Tracy Letts's Pulitzer Prize-winning play of the same name. McGregor starred in the action comedy film Mortdecai (2015), alongside Johnny Depp and Paul Bettany. Robbie Collin of The Daily Telegraph felt the film was "psychotically unfunny". He made his directorial debut with American Pastoral (2016), in which he also starred. In 2017, he reprised his role as Mark Renton in T2 Trainspotting. McGregor played and voiced Lumière (originally voiced by Jerry Orbach in the 1991 animated film) in the live-action adaptation of Disney's Beauty and the Beast, directed by Bill Condon, with an ensemble cast featuring Emma Watson and Dan Stevens in leading roles, alongside Luke Evans, Kevin Kline, Josh Gad, Stanley Tucci, Ian McKellen, and Emma Thompson. Filming began in May 2015 at Shepperton Studios in London, and the movie was released in March 2017. He then starred in FX anthology series in the third season of Fargo (both 2017), which garnered him a Golden Globe Award for Best Actor – Miniseries or Television Film for his dual performance of Emmit Stussy and Ray Stussy at the 75th Golden Globe Awards.
Despite the generally higher volume fraction of rays in hardwoods (typically 15% of wood volume), the rays are not particularly effective in radial flow, nor are the pits on the radial surfaces of fibres effective in tangential flow.
== Variants == The electrosprays operated at low flow rates generate much smaller initial droplets, which ensure improved ionization efficiency. In 1993 Gale and Richard D. Smith reported significant sensitivity increases could be achieved using lower flow rates, and down to 200 nL/min. In 1994, two research groups coined the name micro-electrospray (microspray) for electrosprays working at low flow rates. Emmett and Caprioli demonstrated improved performance for HPLC-MS analyses when the electrospray was operated at 300–800 nL/min. Wilm and Mann demonstrated that a capillary flow of ~ 25 nL/min can sustain an electrospray at the tip of emitters fabricated by pulling glass capillaries to a few micrometers. The latter was renamed nano-electrospray (nanospray) in 1996. Currently the name nanospray is also in use for electrosprays fed by pumps at low flow rates, not only for self-fed electrosprays. Although there may not be a well-defined flow rate range for electrospray, microspray, and nano-electrospray, studied "changes in analyte partition during droplet fission prior to ion release". In this paper, they compare results obtained by three other groups. and then measure the signal intensity ratio [Ba2+ + Ba+]/[BaBr+] at different flow rates. Cold spray ionization is a form of electrospray in which the solution containing the sample is forced through a small cold capillary (10–80 °C) into an electric field to create a fine mist of cold charged droplets.
Abdominal feeding tubes are removed either before or after the arterial injection, and a piece of cotton saturated with phenol used to stop the hole. Sutures may also be used to close the hole. Holes left by intravenous tubes can be left by the embalmer until after the arterial injection, and filler used to restore the contour of the skin. Blisters and sores are opened and drained, and fractured bones are aligned to look as if in a normal state. The embalmer may perform small incisions to align smaller fragments, and irregularities that cannot be smoothed out see the bone fragment removed and filled with wax or putty. The duration of an embalming can vary greatly, but a common approximate time of between two and four hours to complete an embalming is typical. However, an embalming case that presents excessive complications could require substantially longer. The treatment of someone who has undergone an autopsy, cases of extreme trauma, or the restoration of a long-bone donor are a few such examples, and some embalmings may take several days to complete. Embalming is meant to temporarily preserve the body of a deceased person. Regardless of whether embalming is performed, the type of burial or entombment, and the materials used – such as wood or metal coffins and vaults – the body of the deceased will, under most circumstances, eventually decompose. Modern embalming is done to improve the appearance of the deceased and delay decomposition so that funeral services may take place or for the purpose of shipping the remains to a distant place for disposition.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.